Irritable Bowel Syndrome Treatment Study

Irritable bowel syndrome (IBS) affects around 11% of the Global population and as many as 1 in 5 Australians may experience IBS symptoms throughout their lifetime. IBS is a functional condition with symptoms including abdominal pain, bloating, gas, nausea and alternating constipation and diarrhoea.

Research has found that current treatment options for IBS are limited due to the complex pathophysiology of this condition and as such, there is a severe unmet clinical need for products that can treat each of these primary underlying symptoms, and induce and maintain remission in patients.

This clinical study is designed to evaluate the efficacy of a gastrointestinal dietary supplement in IBS patients.

Who can participate?

You may be eligible for this study if you are:

  • 18-65 years old with current IBS symptoms
  • Not currently pregnant or breastfeeding

Study Details:

If you are eligible to be involved in the study, you will be asked to attend the clinic 3 times over a period of approximately 4 months. This includes a run-in period of up to 2 weeks followed by a random allocation into one of three groups, each receiving a different type of medication. You will be asked to take the medication twice a day for approximately 4 months.

Study Locations:

This study is currently looking for participants in NSW, VIC, QLD and WA.

Click here to express your interest